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INTRODUCTION 
 
 
38 years ago it was announced to the world the birth of Louise Brown, first child conceived 
in a test tube, by British scientist Robert Edwards ' Nobel Prize in medicine in 2010. 
Today infertility affects approximately 15-20% of couples in the world, which globally means 
50-80 million people. Latest worldwide estimates indicate that between 2008 and 2010, 
4.461.309 cycles were initiated (Dyer et al., 2016), resulting in the estimated birth of 1.144. 
858 babies, up to 5% of all births in some countries (Kupka et al., 2016). The estimated overall 
number of initiated cycles and of babies born increased by almost 9.5 and 9.1% per annum, 
respectively, during the 3-year period. 
The ongoing global expansion of ART can be attributed both to increased utilization within 
countries where ART is well established as well as the adoption of the technology into 
previously ART naı̈ve countries. 
According to the Italian Assisted Reproduction Technology Register (IARTR), the trends of 
ART initiated cycles per million inhabitants and per million women of reproductive age 
(between 15 and 45 years) were constantly growing from 2005 to 2014, with an increase of 
466 cycles (+ 73.3%) and of 3,172 cycles (+ 118.2%), respectively.  (IARTR registry, 2016).  
Over the years, progress has been made in the field of Reproductive Medicine, passing from 
the first treatments made of spontaneous cycle, to the introduction of medical strategies of 
multiple follicular growth stimulation, which is associated to an improvement of outcomes in 
terms of the number of mature oocytes retrieved, pregnancy rate and live birth rate. 
The next step was the introduction in clinical practice of the hormone GnRH analogues, drugs 
with the aim of preventing premature LH peak, due to cancellation of several cycles. To this 
is associated the need to control the IVF complications, such as the hyperstimulation ovarian 
syndrome (OHSS). 
The clinical introduction of GnRH antagonists, at the end of the years ' 90, opened new 
perspectives in ovarian stimulation strategy. Clinical data obtained from randomized 
controlled trials have shown the benefits of using these drugs in terms of lower dose of 
gonadotropins, shorter duration of treatment, reduced rates of OHSS, with an overall reduction 
of costs (Al-Inany HG et al., 2011). Also permitted the use of GnRH agonists for induction of 
oocyte final maturation, in order to reduce as much as possible OHSS rates. 
The ovarian response to stimulation with exogenous gonadotropins during IVF is a critical 
determinant of live birth rates and adverse outcomes (R.G. Steward et al., 2014; Sunkara et 
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al., 2011). Healthcare providers and national guidelines recognize the need for 
individualization of the starting dose of gonadotropin by using predictive factors related to 
patient characteristics and diagnostic markers of ovarian reserve to attain an optimal oocyte 
yield while minimizing the risk of an excessive response and OHSS. In practice, clinicians 
are required to individualize treatment according to their own experience, using subjective 
preferences for predictive parameters, because there is not a standard position regarding which 
factors to take into account or the weight of each factor when determining the dose. The 
considerable individual heterogeneity in ovarian response to the same dose of gonadotropin, 
the limited performance of baseline patient characteristics including age, FSH, and antral 
follicle count (AFC) in predicting ovarian response, and their inconsistent clinical 
interpretation, as well as the lack of validated dosing algorithms, have limited the 
generalizability of efficacious and safe ovarian stimulation (Fauser at al., 2008). 
Ovarian hyperstimulation syndrome (OHSS) is an uncommon but serious complication 
associated with controlled ovarian stimulation during assisted reproductive technology 
(ART). The incidence of OHSS varies between different types of fertility treatment, with 
treatments involving greater degrees of ovarian stimulation being associated with a higher 
incidence. In cycles of conventional in vitro fertilisation (IVF), mild OHSS has been estimated 
to affect around one-third of cycles, while the combined incidence of moderate or severe 
OHSS varies from 3.1% to 8.  
The 14th European IVF-Monitoring report, analysing data from 25 European countries, found 
an incidence of hospitalization due to OHSS of 0.3% in 2010. Data from the USA showed 
OHSS to be the commonest complication of IVF treatment with an incidence of moderate or 
severe OHSS in 2011 of 1.1%.  
OHSS is rare following ovulation induction with clomifene, or monofollicular ovulation 
induction with gonadotropins, but it has been reported. Very rarely, OHSS may occur 
spontaneously, in association with pregnancy.  
 
This research work was carried out in order to identify the best strategies to improve the 
effectiveness and safety of IVF treatments. The goals are:  
1. To assess how the estradiol serum levels, in the late ovarian stimulation phase, are 
predictive of IVF outcomes, in terms of number of oocytes retrieved, good quality 
embryos, pregnancy rate and live birth rate 
2. To assess GnRh agonist dose for the trigger of final oocyte maturation in order to reduce 
ovarian hyperstimulation (OHSS) rate  
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3. To evaluate the possible long term IVF risks (metabolic, cardiovascular and oncological 
risks) in order to improve safeness 
4. A cost reduction in IVF, by the reduction of cycle cancellation rate due to OHSS risks or 
E2 level drop, and hospitalization rate for ovarian hyperstimulation syndrome (OHSS). 
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The Research Project 
 
 
The research project was carried out with the purpose to identify the best strategies to improve 
the efficiency and safety of Assisted Reproduction Treatments (ART), then the health care 
spending costs.  
 
Target 1 
Effectiveness optimization of controlled ovarian stimulation treatments aimed at IVF in 
terms of improvement in ovarian response to hormonal stimulation (oocyte retrieval, 
embryo quality, pregnancy rate) 
 
 Development of a mathematical model predictive of ovarian response to stimulation 
 Analysis of the dynamic changes of serum E2 in the late phase of COH in IVF 
 Evaluation of the relationship between these changes and the intermediate and final 
outcomes of COH in IVF 
 
 
Target 2  (realized at the Instituto Valenciano de Infertilidad (IVI) in Barcelona) 
Improving the safety of COH treatments,  in order to prevent IVF complications 
 
 Triggering with different doses of gonadotropin releasing hormone (GnRh) 
agonist in oocyte donor cycles: a randomized clinical trial (RCT 
 
 Long term COH complications: metabolic, cardiovascular and oncological risk 
evaluation. An observational, retrospective study  
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Chapter 1: IN VITRO FERTILIZATION 
 
1.1 The steps of in vitro fertilization 
The first attempts to create artificial animal insemination date back to the seventeenth century, 
with failed attempts to M. Malpighi (1628-1694) to fertilize the silkworm, and continue with 
the experiments of Jacopi Wiltheim on salmon and trout eggs and those of the Swedish Clerk 
on the spider. 
In 1782, the Italian Lazzaro Spallanzani made the first artificial insemination in dogs; 3 
puppies are born after 62 days. Thouret in 1785 announced that it had artificially inseminated 
his wife successfully. In 1866 the gynecologist M. Sims reports a pregnancy of 55 attempts at 
intrauterine insemination. Finally, in 1884 Pancoast announced to have successfully 
performed the first artificial insemination with donor sperm. 
From the end of the nineteenth century appear the first experiments to obtain the formation of 
an embryo directly in the laboratory. In 1890 Professor W. Heape reported successful embryo 
transfer from a donor to a recipient female rabbit, with the establishment of a full-term 
pregnancy, representing the first example of a surrogate pregnancy. In 1944, two American 
biologists, Rock and Menkin, describe successful in vitro fertilization of human eggs and their 
development stage of embryos for two three cells. In 1969, Edwards, in England, he obtained 
human embryos by performing in vitro fertilization. In 1976 Steptoe and Edwards got the first 
pregnancy from IVF, unfortunately ectopic; on November 10, 1977, they performed the 
transfer of an eight-cell embryo and on July 25, 1978, at 23:57, at a hospital in Oldham 
(Manchester), born Louise Joy Brown, the first test-tube baby conceived after more than 600 
attempts, . On January 11, 1982 in a private clinic in Naples, born Alessandra Abbisogno the 
first Italian child conceived through IVF. The On December 20, 2006, in Bristol, Louise 
becomes a mother, giving birth to a child (conceived naturally). In 2010, Edwards was 
awarded the Nobel Prize in Physiology or Medicine "for the development of in vitro 
fertilization". 
In just over 30 years, in the world, more than 3 million children conceived through IVF. were 
born. In Italy, according to data of the Ministry of Health, in 2008 approximately 59,000 
couples have undergone assisted reproduction techniques for a total of 80,000 initiated cycles, 
12,767 pregnancies and 10,825 children born. 
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1.2 The Development of Ovarian Stimulation Agents  
 
Evidence of the endocrine pituitary-gonadal axis arose early in the 20th century when it was 
observed that lesions of the anterior pituitary resulted in atrophy of the genitals. The first 
convincing evidence supporting the existence of two separate gonadotropins (initially referred 
to as Prolan A and Prolan B) was provided by Fevold et al. in 1931 (1), and both LH and FSH 
were subsequently isolated and purified. In 1928, Ascheim and Zondek (2) described the 
capacity of urine from pregnant women to stimulate gonadal function. The concept of 
stimulating ovarian function by the exoge- nous administration of gonadotropin preparations 
has in- trigued investigators for many decades. In 1940, Hamblen (3) reported the ability of 
purified pregnant mare serum to induce ovulation in humans by iv administration. However, 
these early attempts had to be stopped due to species differences and resulting antibody 
formation impacting on ef- ficacy and safety. Clinical experiments in the late 1950s 
demonstrated that extracts derived from the human pituitary could be used to stimulate 
gonadal function (4). Subsequently, experiments involving the extraction of both the 
gonadotropic hormones LH and FSH from urine of post- menopausal women led to the 
development of human menopausal gonadotropin (hMG) preparations. From the early 1960s, 
these were used for the stimulation of gonadal function in the human (5). A second important 
development allowing for ovarian stimulation on a large scale arose when the first estrogen 
antagonist tested in cancer patients was found to induce ovulation.  
 
1.2.1 The discovery of clomiphene citrate  
In the late 1950s, the first nonsteroidal estrogen antagonist (MER-25) was tested for the 
treatment of breast cancer and endometrial hyperplasia. The administration of CC in women 
with endometrial hyperplasia suffering from secondary amenorrhea was followed by the 
recommencement of menstrual cycles (6). Shortly thereafter, the ovulation- inducing capacity 
of a closely related antiestrogen (MRL/41) was recognized (7).  
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CC was originally developed for clinical use by the Merrel company in 1956. Nearly 50 yr 
later, it is still considered to represent the first line treatment strategy in most anovulatory 
infertility and is still the most applied drug for infertility therapies worldwide.  
CC is an oral antiestrogen consisting of a racemic mixture of two stereoisomeres. Stimulation 
of ovarian function is elicited by raised pituitary FSH secretion due to blockage of E2 steroid 
feedback by CC. Overall, a 50 – 60% increase of serum FSH levels above baseline has been 
described (8-10). The exact nature of the mechanism of action of CC is still uncertain (8-10), 
but induced changes in the IGF system may also be important (10). CC for ovulation induction 
in anovulatory women is considered to be relatively safe because steroid negative feedback 
remains intact. The oral route of administration and low costs represent additional advantages 
of this preparation. After the first IVF baby born in a natural cycle (11), four normal IVF 
pregnancies were subsequently reported after ovarian stimulation with CC (12). In the 
following years, many groups reported IVF results after CC, with or without gonadotropin 
cotreatment (13,14). 
 
1.2.2. Gonadotropins  
Human menopausal gonadotropins first became widely used for IVF in the United States 
(15,16). For over two decades, gonadotropin preparations have also been exten- sively applied 
for ovarian stimulation in ovulatory women for empirical treatment of unexplained 
subfertility. The aim is to increase the number of oocytes available for fertilization in vivo 
(17).  
The initial preparations were very impure with many contaminating proteins; less than 5% of 
the proteins present were bioactive. However, improved protein purification technology 
allowed for the production of hMG with reduced amounts of contaminating nonactive proteins 
and eventually the development of purified urinary FSH (uFSH) preparations by using 
monoclonal antibodies since the early 1980s (5). The currently available pure products allow 
for less hypersensitive reactions and less painful sc administration. Due to the worldwide 
increased need for gonadotropin preparations, demands for postmenopausal urine increased 
tremendously, and adequate supplies could no longer be guaranteed. 
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Through recombinant DNA technology and the transfection of human genes encoding for the 
common - and hormone-specific -subunit of the glycoprotein hormone into Chinese hamster 
ovary cell lines (21), the large scale in vitro production of human recombinant FSH (recFSH) 
has been realized (22,23). The first pregnancies using this novel preparation in ovulation 
induction (24) and in IVF (25,26) were reported in 1992. Since then, numerous, large-scale, 
multicenter studies have been undertaken demonstrating their efficacy and safety. The 
recombinant products offer improved purity, consistency, and large-scale availability. 
Because of its purity, recFSH can now be administered by protein weight rather than 
bioactivity, and so-called “filled- by-mass” preparations are now available for clinical use. 
During recent years, recombinant LH (recLH) and hCG (rechCG) have also been introduced 
for clinical application.  
 
1.2.3. GnRH agonists  
 
In 1971, the small decapeptide GnRH was isolated, and its structure was elucidated (25,26). 
This decapeptide is secreted by the hypothalamus into the portal circulation in an intermittent 
fashion stimulating the pituitary gonadotropes to synthesize and secrete LH and FSH (27).  
In 1978, it was discovered that repeated administration of GnRH agonists produced a transient 
increase in gonadal function followed by a decrease in gonadal function and a significant fall 
in sex steroids (28,29). Although initial binding to GnRH receptors results in activation, 
continuous occupation leads to desensitization due to the clustering and internalization of 
pituitary GnRH receptors, resulting in falling LH and FSH levels (30). If the agonists are 
administered for a period of several months, LH levels remain suppressed, but FSH levels 
return to normal and eventually rise to supraphysiological levels (31).  
Pulsatile administration of GnRH was established as an effective and safe means of treating 
hypogonadotropic hypogonadal anovulation (29-32). The first reports concerning its use for 
the prevention of a premature LH rise during ovarian stimulation appeared in the early 1980s 
(33-35). During initial studies with hMG stimulation of multiple follicle development for IVF, 
it became apparent that a prema- ture LH peak occurred in 20–25% of cycles due to positive 
feedback activity by high serum E2 levels during the mid- follicular phase of the stimulation 
cycle (35).  
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This advanced exposure to high LH was associated with premature luteinization of follicles 
and either cycle cancellation due to follicle maturation arrest or severely compromised IVF 
outcomes. The clinical development of GnRH agonists allowed for the complete suppression 
of pituitary gonadotropin release during ovarian stimulation protocols for IVF (33, 36–38). 
Induced pituitary down- regulation indeed resulted in significantly reduced cancellation rates 
and improved overall IVF outcome (39). More- over, the approach of GnRH agonist 
cotreatment facilitated scheduling of IVF and timing of oocyte retrieval.  
 
In the long protocol, GnRH agonist treatment usually commences in the luteal phase in the 
preceding cycle and is continued until hCG administration. Due to the intrinsic agonist activity 
of the compound, pituitary down-regulation is preceded by an initial stimulatory phase 
(referred to as the “flare” effect). This flare effect renders the approach of GnRH agonist long 
protocol for ovarian stimulation time consuming, because ovarian stimulation can only 
commence when pituitary quiescence has occurred, usually around 2 wk after commencing 
treatment (40). It is uncertain whether ovarian response to exogenous stimulation is affected 
by GnRH agonist cotreatment (41), and some women suffer from serious hypoestrogenic side 
effects, such as mood changes, sweating, and flushes.  
The “short” or “flare-up” protocol combines GnRH agonist therapy, started at cycle day 2, 
with gonadotropins initiated one day later (42). The immediate stimulatory action of the 
GnRH agonist serves as the initial stimulus for follicular recruitment. Adequate follicular 
maturation is on average reached in 12 d, which should allow enough time for sufficient 
pituitary desensitization to prevent any premature LH surges (43).  
Several investigators have tried to shorten the duration of GnRH agonist administration by 
early cessation, because pituitary recovery after cessation takes around 14 days (44). The 
GnRH agonist is started in the midluteal phase of the preceding cycle and discontinued during 
or even before the FSH treatment is started. Several prospective randomized con- trolled 
studies have been performed comparing this ap- proach with the long protocol (44–48). 
Although premature rises in LH did not occur (confirming delayed pituitary recovery from 
desensitization), no clear clinical benefit has been demonstrated by this approach.  
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A meta-analysis comparing short and long IVF protocols showed a higher number of oocytes 
retrieved and higher pregnancy rates in the long protocol, although more units of gonadotropin 
were needed (49). In terms of gonadotropin suppression and number of retrieved oocytes, the 
midluteal phase of the preceding cycle is the optimal moment for the initiation of the GnRH 
agonist, in comparison to the follicular, early, or late luteal phase (50,51). A major clinical 
advantage of the long protocol of GnRH agonist administration is the contribution to the 
planning of the oocyte retrieval because the initiation of exogenous gonadotropins after 
pituitary desensitization can be delayed, without a detrimental effect on IVF outcome (52, 53). 
A potential disadvantage with the luteal phase initiation of GnRH agonist is that spontaneous 
pregnancy present at the time of commencing treatment cannot be excluded with certainty. 
The extensive evidence supporting the long protocol has led to its widespread adoption as the 
standard of care (49). However, the recent clinical introduction of GnRH antagonists may 
ultimately lead to a new standard of care in IVF practice.  
 
 
1.2.4. GnRH antagonists  
GnRH antagonists may be administered at any time during the early or midfollicular phase of 
a treatment cycle to prevent a premature LH rise. Several studies have been performed to 
determine the minimal effective dose and treat- ment schedule in IVF patients (54, 55). Two 
general ap- proaches have emerged.  
In the single-dose protocol, one injection of 3 mg cetrorelix (ganirelix is not provided in this 
depot formulation) is administered in the late follicular phase on stimulation day 8 or 9. This 
is sufficient to prevent a LH surge in 80% of women (55).  
In the multiple-dose GnRH antagonist protocol, 0.25 mg cetrorelix or ganirelix is given daily 
from the sixth day of gonadotropin stimulation onward (54, 56). The rationale behind starting 
GnRH antagonist at least 5 d after commencing stimulation with gonadotropins is based on 
the reduced possibility of observing a premature LH rise in the early follicular phase (57).  
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Four large, industry-sponsored, prospective multicenter clinical trials comparing daily GnRH 
antagonist injections with long GnRH agonist protocols in IVF patients undergoing ovarian 
stimulation have been reported (58-60). With a GnRH antagonist, the duration of 
gonadotropin treatment is shortened by 1–2 d, and slightly fewer follicles are seen at the time 
of hCG injection compared with a GnRH agonist. Therefore, the number of recovered oocytes 
tends to be lower. In these studies, no significant difference was found with respect to 
percentages of metaphase II oocytes, fertilization rates, and number of good quality embryos. 
Pregnancy rates were adequate in both groups in all four studies, but in every one the absolute 
rate was lower in the GnRH antagonist group. A meta-analysis of five large randomized trials 
showed an overall decrement in pregnancy rate of 5% (odds ratio, 0.75; 95% confidence 
interval, 0.62–0.97) (62)  
It has been hypothesized that the lower observed pregnancy rates may be a consequence of 
the currently advised treatment regimen. It has been suggested that the larger numbers of 
oocytes and embryos with agonists allow better selection, although the numbers of good 
quality embryos do not seem to be different. The GnRH antagonist was started on a fixed day 
of stimulation (d 6) in these studies, which may be too early for some patients and may lead 
to a diminished number (and quality) of oocytes.  
Studies comparing the fixed antagonist protocol with a flexible protocol, in which the daily 
antagonist administration is started when at least one follicle reached a size of 14 mm, showed 
no differences in IVF outcome, except that the dose of GnRH antagonist was reduced in the 
flexible protocol (63). When GnRH antagonist is commenced, there appears to be no 
requirement to increase the dose of FSH (64,65) or supplement LH (66). Commencing GnRH 
antagonist in the late follicular phase enables the endogenous FSH rise to be harnessed to 
commence ovarian stimulation and then supplemented by exogenous gonadotropin 
stimulation from the midfollicular phase onward to achieve multifollicular development (67). 
This approach is cost-effective and patient-friendly alternative to standard stimulation 
regimens.  
Based on the inverse association between implantation rates and ganirelix dose in the higher 
dosage groups in the large dose-finding study (68), direct effects of GnRH antagonists on 
human embryos have been suggested. Adverse effects were not observed on the freeze-thaw 
embryos of these cycles (69). Moreover, retrospective comparison of pregnancy rates after 
transfer of frozen-thawed two-pro-nucleate oocytes obtained in either a long GnRH agonist 
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protocol (or a GnRH antagonist protocol) showed no differences in implantation, pregnancy, 
or miscarriage rates (70).  
The availability of gonadotrophin-releasing hormone (GnRH) antagonists for ovarian 
stimulation protocols has generated many meta-analyses comparing it to GnRH agonist long 
protocols. (71-75). These meta-analyses have yielded conflicting results for pregnancy rate, 
with a tendency toward a better outcome for GnRH agonists. Recently, a Cochrane review 
seems to have settled the conflicts by demonstrating no evidence of statistically significant 
differences in the rates of live births or ongoing pregnancies when comparing GnRH agonist 
long protocols with GnRH antagonist protocols. Furthermore, the use of the GnRH antagonist 
protocol has made possibile the use of GnRH agonist for the final trigger, minimizing the risk 
of hyperstimulation ovarian Syndrome (OHSS).   
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CHAPTER 2 - TARGET ONE 
 
Effectiveness optimization of controlled ovarian stimulation (COH) in IVF treatments  
terms of improvement in ovarian response to hormonal stimulation (oocyte retrieval, 
embryo quality, pregnancy rate)  
 
 Development of a mathematical model predictive of ovarian response to stimulation 
 Analysis of E2 serum dynamic changes in the late phase of the COH cycle  
 Evaluation of the relationship between these changes and the intermediate and final 
outcomes of COH cycle 
 
 
2.1 MATERIALS AND METHODS  
 
We carried out a retrospective study of 1116 consecutive IVF homologous cycles at the 
Assisted Reproductive Unit of IRCCS Burlo Garofolo, Department of Medical, Surgical and 
Health Sciences, University Of Trieste (Italy) from January 2013 to January 2016. The data 
collected for each patient were: age at the time of the procedure; body mass index (BMI); 
third day hormonal dosage; number of the years of infertility; type of infertility (primary or 
secondary); cause of infertility (male factor, ovulatory factor, tubal factor, endometriosis, 
multiple factors, idiopathic infertility). 
 All the patients underwent ovarian stimulation (COH) with tailored protocol. For each 
cycle, the following variables were considered: data relating to the type of COH protocol used 
(GnRH agonist long protocol or GnRH antagonist flexible-dose protocol); the maximum 
estradiol (E2) serum concentration on the trigger day with hCG; the duration of stimulation 
(days) and gonadotropin total dose used. 
A written consent form for all the patients who underwent an IVF treatment was required. All 
the patients consented to the use of anonymous data for research purposes. 
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 Ovarian stimulation protocol 
 Starting on cycle day 2, the patient received 150 - 225 UI/die s.c. of recombinant- Follitropin 
(r-FSH) with or without human Menopausal Gonadotropin (hMG). Ovarian response was 
monitored with vaginal ultrasound and plasma estradiol. The first control was performed on 
day 5 of the cycle. The FSH or hMG dose was then adjusted according to the ovarian response. 
Recombinant or Human chorionic gonadotropin was given to induce ovulation when at least 
two follicles 18 mm in diameter were present.  
Oocyte retrieval was performed 35 hours after the ovulation induction. IVF or ICSI technique 
were chosen, depending on the cause of infertility. The fertilization was determined by the 
presence of two pronuclei (2PN) using an invertoscopio the first day after insemination. The 
embryos were classified into grades I to V, based on the number of blastomeres and uniformity 
and the percentage of fragmentation, according to the classification of Veeck system. The 
embryo transfer procedure took place 48-72 hours after the oocyte retrieval. The luteal phase 
was supplemented with a daily dose of 50 mg progesterone in oil or 600 mg of vaginal 
micronized progesterone. On the 15th day after ovum pick up, pregnancy test was performed.  
 
 Statistical Analysis 
We evaluated the 17beta-E2 levels at 96 and 48 hours before eggs retrieval. The dynamic 
changes of serum E2 were evaluated by calculating the increase or decrease rate of the E2 at 
96 h and 48 h prior to oocyte retrieval.  
Then, we identified a coefficient of E2  increase or decrease, using a mathematical formula. 
In this way we were able to identify four different coefficient categories: a negative 
coefficient, with a negative increase (category A); a positive coefficient with an increase 
between 0 and 50% (category B), a positive coefficient with a an increase between 50 and 
100% (category C);  a positive coefficient with a increase more than 100% (category D).  
For each coefficient category, the correlation with the IVF outcomes was analyzed.  
The final outcomes were: the total number of retrieved oocytes, the number of mature oocytes 
(metaphase II), the ratio of mature oocytes and total oocytes, the fertilization rate, the total 
number of embryos, the number of good quality embryos (grades I-II), the ratio between 
embryos of good quality and total embryos, the implantation rate, the clinical pregnancy rate 
and the live birth rate.  
One-way ANOVA, Kruskal Wallis test and Dunn's Multiple Comparison Test were used for 
the analysis of the continuous variables, whereas for the categorical variables a Chi-square 
text was chosen. Statistical analysis was performed using GraphPad Prism 5 software. 
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 2.2 RESULTS 
 
In this retrospective study, we analysed 1116 consecutive IVF homologous cycles. The mean 
age of patients was 37.25 years (SD 4.19), the average BMI was 22.67 (SD 3.51), the value 
of FSH on day 3 of the menstrual cycle was 7.26 (SD 2 , 66). The majority of cycles was 
performed on patients with primary infertility (876/1116 cycles). The most common cause of 
infertility was male factor (613 cases out of 1116 cycles), followed by idiopathic factor 
(84/1116 cycles), tubal factor (71/1116 cycles), endometriosis (26/1116 cycles), ovulatory 
factor (19/1116 cycles); in 303 cases the cause was mixed (male and female factor).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variables Mean 
Age (years) 37,25 y 
BMI (kg/m2) 22,67 
Basal FSH 7,26 
Type of infertility  
Primary 876 
Secondary 240 
Causes of infertility  
Male factor 613 
Ovulatory factor 19 
Tubal factor 71 
Endometriosis 26 
Idiopathic 84 
Mixed female and male factor 303 
Days of COH 11,9 
COH protocol  
Long Gnrh agonist protocol 671 
GnRh antagonist protocol 445 
FIV-ET cycles 305 
ICSI cycles 756 
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Of all performed cycles, in 671 we used a long agonist protocol and in 445 a GnRH antagonist 
flexible-dose protocol for the COH. Conventional FIV was carried out in 305 patients, while 
ICSI was carried out in 756 cases. The mean dose of gonadotropins used was 2707 IU (1464 
IU SD); the mean duration of stimulation was 11.94 days (SD 3.53). The mean value of E2 at 
the trigger time was 1,490.57 (SD 797.86). 
Oocyte retrieval was realized in 1085 cycles out of 1116 (for a total of 7426 oocytes retrieved): 
in 17 cycles no mature oocytes (MII) were retrieved.  
 
In 13 cases out of 1116 we didn’t perform the insemination, due to altered oocyte morphology 
(8/1116) or due to the absence of semen sample (5/1116). The fertilization rate was 67.68%.  
 
We carried out the embryo transfer (ET) only in 904 cycles out of 1116: in 197 an embryo 
degeneration before the ET was observed. A maximum of 3 embryos was transferred for a 
single cycle.  
 
In 15 cases, we cryopreserved embryos to prevent the onset of the hyperstimulation ovarian 
syndrome (OHSS). The implantation rate was 11.26%; the pregnancy rate was 16.22% per 
OPU and 20,0% for ET; the live birth rate per OPU was 14.78%, while it was 18.25% per ET 
(table 1.) 
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TOTAL CYCLES  1116 
No oocyte (n. cicles)  31 
No M2 oocyte (n. cicles)  17 
No insemination (n cicli) 
No good quality oos (n cicles) 
No sperm (n cicles) 
 
 
61 
56 
5 
Fertilization rate (%)  67,68 
Embryo transfers (n cicles)  904 
No ET for OHSS risk (n cicles)  15 
Implantation rate (%)  11,26 
Clinical pregnancy rate (%) 
Per OPU 
Per ET 
 
 
 
16,22 
20,02 
Live birth rate  
Per OPU 
Per ET 
 
 
 
14,78 
18,25 
Table 1 
 
For all the cases we observed an asymmetric distribution for demographic characteristics (eg. 
age and the basal values of FSH) and for other parameters associated with COH, such as the 
doses of gonadotropins and the number of days of stimulation. 
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We identified a coefficient of E2  increase or decrease, using a mathematical formula. 
 
 
E2 coefficient (%) = (E2 48h before OPU - E2 96h before OPU) 
E2 96h before OPU 
 
 
 
 
Then, according to the E2 dynamics changes during COH, we observed 4 different categories 
of E2 increment coefficients of E2 values, with this patients distribution:  
1. category A (decreasing trend in estrogen levels): 104 cycles out of 1116 
2. category B (E2 increasing trend between 0 to 50%): 277 cycles out of 1116 
3. category C (E2 increasing trend between 50 and 100%): 445 cycles out of 1116 
4. category D (E increasing trend > 100%): 290 cycles out of 1116 
5.  
 
The patients distribution in each category is similar for BMI, but not for age and FSH basal 
values: in fact, there are significant differences between A and B and A and C groups if the 
age of the patients is compared. Significant differences are observed between the groups A 
and B and the B and D groups for the FSH basal values (table 2).  
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Table 2 
 
 
Furthermore, we observed a significant association between a shorter COH duration and the 
E2 increase trend in 48 h greater than 100% (group D; p <0.0001) (Table 3). 
 
 
 
STIMULATION DAYS 
E2 COEFFICIENTS A B C D 
N cases 104 277 445 290 
Median 12,00 12,00 12,00 12,00 
25°-75° centile 11,00-13,00 11,00-13,00 11,00-13,00 10,00-12,00 
Mean  11,98 12,60 11,94 11,30 
SD 1,86 6,35 1,76 1,70 
Table 3 
 
 
 
We observed significant differences between the groups with different E2 coefficient of 
Increase (p<0.0001). However, no differences were observed within the same category of E2 
increase, if we compare long GnRh agonist protocol with GnRH antagonist one (p> 0.05). 
According to the  COH protocol used, we observed statistically significant differences on the 
mean doses of the gonadotropins used (p <0.0001). In particular, we found a lower use of 
gonadotropins in patients of category D (E2 negative increase).  
  
 Age               BMI Day-3 FSH 
E2 coefficient Mean SD  Mean SD  Mean SD 
A 35,86 4,77  22,45 3,49  6,66 2,15 
B 37,34 4,17  22,46 3,36  7,70 2,84 
C 37,56 4,14  22,78 3,50  7,23 2,67 
D 37,22 3,97  22,65 3,67  7,12 2,95 
P value 0,0065  0,4547  0,0072 
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Regarding the total number of oocytes retrieved, we observed statistically significant 
differences between categories A and B, A and C, B and C, B and D (p <0.0001); there are no 
differences in the total number of eggs retrieved between groups A and D, C and D (p> 0.05). 
Statistical differences were observed about the number of mature oocytes (MII) between 
categories A and B, A and C, B and D (p <0.0002).  
Regarding the total number of oocytes retrieved according to the protocol used, for the agonist 
protocol we observed a statistical difference between B and D group, in favour of D (E2 
trend>100%); in the antagonist group, we observed a statistical correlation between A and B, 
and between A and C (p < 0,0001). We observed the same statistical correlation, for the 
antagonist protocol, when we analysed data about the mature oocyte retrieved (A and B, A 
and C). 
 
 
 
 
 
T 
Total oocyte and M2 oocyte according to COH protocol (agonist protocol 1; antagonist protocol 2) 
 
 
A1 A2 B1 B2 C1 C2 D1 D2
numero di cicli 40 64 107 170 285 160 239 51
Mediana 9,5 7 5 4 6 5 7 5
25% - 75% Percentile 4,00 - 12,75 4,00 - 11,75 3,00 - 7,00 2,00 - 7,00 4,00 - 9,00 3,00 - 7,75 4,00 - 11,00 2,00 - 8,00
n. massimo ovociti 27 22 19 22 22 16 23 24
Media 9,25 8,031 5,916 5,424 6,863 5,481 7,665 6,314
SD 6,428 5,279 4,098 4,116 4,236 3,433 4,846 5,857
Mediana 7 6 4 4 5 4 5 4
25% - 75% Percentile 3,00 - 9,75 3,00 - 10,00 2,00 - 7,00 2,00 - 7,00 3,00 - 8,00 2,00 - 6,00 3,00 - 9,00 2,00 - 8,00
n. massimo ovociti 19 20 18 21 19 14 18 20
Media 6,575 6,984 5,084 4,806 5,674 4,738 6,05 5,667
SD 4,414 4,712 3,699 3,709 3,745 3,083 3,991 5,328
ovociti totali
ovociti M2
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We didn’t observed any difference between the number of total embryos and different E2 
growth trends, nor between good quality embryos (grade I and II) and different E2 growth 
trends.  
            
 
Later, we compared the 4 different groups of E2 increase with the fertilization rate (FR), the 
implantation rate (IR), the clinical pregnancy rate (CPR) and live birth rate (LBR).  
We found a significant difference in clinical pregnancy rate per embryo transfer (ET) between 
A and D categories (p=0.0445), but not for the other groups (p> 0.05). When we compared the 
same categories A and D in terms of clinical pregnancy rate for ovarian pick up (OPU), live 
birth rate per OPU and live birth rate for ET we found a P value near to statistical significance 
(respectively 0.0727; 0.0938; 0.0593). 
After a further analysis of the IR data, on the basis of the different E2 increase coefficients 
groups and the type of COH protocol, in the group A (decreased E2 levels) a difference in the 
IR between agonist (7 gs out of 46 embryos) and antagonist protocol (16 gs out of 102 
transferred embryos) is observed (p = 0.006); the same difference was observed in the D group 
(E2 levels increased by 100%) (52 gs out of 383 embryos in the agonist protocol versus 3 gs 
out of 68 embryos transferred in the antagonists protocol) (p = 0.042) . 
In the GnRH agonist group we observed that the IR of group A is higher than the one observed 
in groups B, C and D (p value 0.004 respectively; 0.0002; 0.0002). In the GnRH antagonist 
protocol, we found a lower IR in group D than in group A, B and C (p value respectively 0.025; 
0.022; 0.034). 
We observed no differences in CPR per OPU and ET, and in LBR per OPU and ET.  
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2.3 DISCUSSION 
  
  
  
Clinicians’ ability to predict clinical outcomes before or during the course of IVF treatment is 
limited although numerous predictors are available, such as patients’ age (1), basal FSH/LH 
ratio (2), embryo quality parameters (3,4) serum progesterone level (5,6) and estradiol (E2) 
level (7,8). Among these predictors, the serum E2 level is one of the most important factors 
because E2, a major product of granulosa cells, reflects the maturity of follicle and quality of 
oocytes (9,10) Accordingly, monitoring serum E2 level closely is the main way of evaluating 
the ovarian response, and serum E2 levels at different time points, such as basal E2 level, E2 
level at the stimulation day 5 and on the day of hCG administration, as well as in the mid-
luteal phase, have been documented in many papers as predictors of clinical outcomes 
(7,8,11–13).  
Several authors have examined the effect of estradiol trends on IVF success, including the 
absolute value of day 5 E2 (3) Day 6 E2 (4), the trend of E2 from day 5 to the day of hCG , 
and the early response of E2 between day 0 and 6 (5). 
Styer et al., in 2005 evaluated the effect of an unpredictable drop in serum estradiol prior to 
hCG administration on pregnancy outcomes in vitro fertilization cycles. The authors 
concluded that, in the absence of coasting, a drop in serum estradiol levels during GnRH-
agonist downregulated controlled ovarian stimulation (COS) for IVF prior to hCG is not 
associated with a decrease in live birth rates or pregnancy loss rates. 
Kim et al., in their study in 2010 investigated the effects of total E2 production during COS, 
calculated by ‘‘modified area under the curve for E2 (mAUC-E2)’’ and of the changes in E2 
level during the initial stimulation period calculated as ‘‘slope of initial increase in E2 (Sl-
E2)’’ on the outcomes of IVF cycles using GnRH antagonist protocols. They concluded that 
the rate of initial increase in E2 rather than total E2 production during COS might affect the 
competence of retrieved oocytes in GnRH antagonist cycles. Surveillance on the initial change 
in E2 and subsequent modulation of stimulation could be beneficial in achieving optimal IVF 
outcomes in GnRH antagonist cycles.  
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Other studies suggest that E2 levels double in the late stages of IVF stimulation, meaning that 
there is a 100% increase every 2 days (14).  
Our study aimed to identify serum E2 production variation during IVF controlled ovarian 
stimulation, through the development of a mathematic model able to identify the increasing 
and decreasing E2, in the late phase of ovarian stimulation, between 96 and 48 hours before 
ovarian retrieval. 
The hypothesis was that E2 values follow a linear increase; to prove that we calculate the 
angular coefficient of the straight line, normalising this coefficient to the E2 value 96 hours 
before the oocytes retrieval: so, we used a dynamic index of E2 production that allowed us to 
analyse its role independently from the pure E2 levels. 
 
 E2 coefficient (%) = (E2 48h before OPU - E2 96h before OPU) 
E2 96h before OPU 
 
 
To evaluate the effects of a decrease or increase of E2 levels, we divided the population in 4 
categories:  
- Category A (E2 decrease) 
- Category B (E2 increase between 0 and 50%) 
- Category C (E2 increased between 50 and 100%) 
- Category D (E2 increase >100%) 
 
The index we used is different from the one used by other authors to evaluate the growth of 
E2 values: Shapiro et al. evaluated the difference between oestrogens levels the day of GnRH 
antagonist administration and the day of the second GnRH antagonist dose administration 
(17); Scotchie et al. examined the ratio of E2 serum levels before and after the antagonist 
administration (E2 after GnRH antagonist/E2 before GnRH antagonist), analysing the results 
in relation to the number of days of GnRH antagonist administration (16) Ranieri (18) and 
Ravhon (19) instead, considered estrogenic values after buserelin acetate administration, 
evaluating the difference between day 3 and day 2 of the menstrual cycle or, in other words, 
before and after the GnRH antagonist consumption. Kim et al. (15) considered the percentage 
of E2 level increase at the beginning of the cycle, considering the difference between the level 
at the first r-FSH administration and the 5th day of the stimulation, and moreover  
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they calculated the area under the curve of oestrogen levels at the beginning, middle and at 
the end of the stimulation.  
There is a considerable difference between the studies in the criteria chosen to represent the 
dynamic changes of E2 levels, making difficult to compare the methods utilized and to 
evaluate their efficacy. Studies that evaluated late changes of oestrogen levels reported 
heterogeneous results; on the opposite, studies that analysed the effects of E2 changes in the 
first stages of stimulation agree on the possible correlation between dynamic index and 
outcome of the IVF procedure (15,19).Therefore, it is possible that changes of the E2 
production in the first days of the stimulation correlate with oocytes quality at retrieval, 
meaning that monitoring E2 levels after COH is a poor predictor of the number of oocytes 
collected. However, serial monitoring in the advanced stages of stimulation allows better 
control of the final follicular recruitment, adjustments of drugs dose in case of hyper response 
to the therapy and to evaluate the effects of subsequent therapeutic changes.  
Analysis of the data showed that a decrease in oestrogen levels is not frequent in the general 
population under IVF treatment: in our study it happens in 9% of the population study, a result 
similar to the 6% reported in the literature (17) Furthermore, we observed that lower E2 levels 
are usually present in younger patients, that they require lower mean doses of gonadotropin 
and had a good total number of retrieved and mature oocytes compared to the general 
population, but the implantation and pregnancy rate is the same of the patients that do not 
have a decreasing level of E2; we also saw that patients with a E2 increasing level more than 
100% are characterized by, for the same age, lower need for gonadotropin assumption and 
higher retrieval of mature oocytes compared to patient with a E2 increment of 100% or lower, 
but the implantation and pregnancy rate is lower if GnRH antagonist was used.  
Our data differ from what observed by Scotchie et al. (16) as these authors found a higher 
oocytes retrieval after administration of GnRH antagonist: in their study, patients with lower 
or steady trend of E2 levels were significantly older, required a higher mean use of 
gonadotropin compared to the general population, but E2 levels were lower in the 48 hours 
before the oocytes collection. In our study, the small number of patient in the group with a 
lowering trend might have influenced the results. However, it is possible that younger patients, 
characterized by a bigger ovarian reserve, may request lower gonadotropin doses throughout 
the stimulation but at the same time they could need more frequently changes in gonadotropin 
dose based on the follicular response, resulting in drastic changes of E2 levels at the later 
stages of stimulation, with a decreasing or rapidly increasing trend. Since the younger age, the 
possibilities of an on-going pregnancy are higher. 
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Moreover, it is possible that the higher increase of E2 levels at the time of ovulation induction 
might affect also the endometrial quality with consequences on the implantation and 
pregnancy rate.    
We also analysed the relationship between dynamic changes of serum estradiol and IVF 
results in relation to the stimulation protocol chosen (GnRH agonist vs GnRH antagonist). 
Regarding GnRH agonist, we found that gonadotropin administration was lower in the groups 
with extreme changes in E2 levels. We observed differences in oocytes retrieval between 
group B and D but not in relation to other groups. Differences in E2 increase didn’t affect 
results in term of mature oocytes retrieved, number of total embryos at the time of embryo 
transfer and number of good quality embryos.  
If we compare different increasing trend of E2 based on the GnRH protocol used, we found 
that the implantation rate is higher in the lowering E2 levels group; if we compare the 
implantation rate in the agonist and antagonist group we see that it is higher in group A and 
D. These data indicates that in the GnRH protocol, the increasing E2 trend at the end of ovarian 
stimulation does not impact on the outcome of the cycle.  
Our data are similar to the one of Simon (20) who found that there is no relationship between 
E2 levels and embryonic quality. In our study we didn’t observe any relationship between E2 
levels and pregnancy rate: it is possible that, to predict the outcome of ovarian stimulation 
with GnRH agonist, the absolute E2 level at the time of hCG administration is far more 
important than the oestrogens trend; this conclusions is supported also by some studies that 
find an impact of the E2 levels on the endometrial receptivity (20,21)  
In our population we found that, if GnRH antagonists were used, the number of the total 
oocytes and mature oocytes collected was higher in the group with a negative coefficient of 
E2 levels, but there were no differences in regard of total number of embryos and good quality 
embryos. As already said, it is possible that this is the consequence of a younger age 
population and thus more responsive to ovarian stimulation, both in qualitative and 
quantitative terms. Furthermore, this result support our thesis that a lowering trend of E2 levels 
in the final days of the stimulation is not always a critical reason to withdraw the cycle, 
contrasting with what reported previously in the literature. (16).  
No differences in reduction of implantation and pregnancy rate were found in the lowering E2 
level group; we also saw that the implantation rate was lower in the group of patient with an 
increase of E2 levels higher than 100% of the starting level, most likely because of a 
detrimental effect on the endometrium.  
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Considering that GnRH administration gives an instant suppression of endogen LH, it was 
speculated that it could affect also E2 levels. Although data are limited, some clinicians 
suggested that an abnormal E2 pattern (plateau, decrease) after antagonist administration 
might affect the clinical outcomes (23) In our data, not only we didn’t find any difference in 
the clinical outcomes based on the different oestrogen increasing levels, but we also found 
that a decreasing E2 levels was not frequent. Moreover, the absence of relationship between 
implantation rate, pregnancy rate and live birth rate may be a consequence of the different 
effect of GnRH antagonist on the endometrial quality.  
Our data show that, in case of ovarian stimulation with GnRH antagonist, the E2 patterns with 
a decreasing or plateau trend do not affect the clinical outcomes of the IVF procedures, as in  
Shapiro and Scotchie studies (16,17). But our data are in contrast with Lindheim conclusions 
(24) who claims that a drop in E2 levels, after GnRH antagonist administration, affects the 
IVF outcomes negatively, also in case of an egg donor cycle.  
With this study we were able to highlight that dynamic changes of estradiol levels during 
ovarian stimulation don’t affect the outcome of IVF procedure.  
Our results are in line with other few studies that analysed the relation between the index used 
during the controlled ovarian stimulation and the IVF procedure results. The majority of the 
reported data were obtained from the analysis of small population groups, which not always 
represent the entire sample of women seem in  II and III level IVF centres.  
This study, though the limited nature of a retrospective study, is characterized by a good 
sample of population analysed and by the study of dynamic changes of oestrogen levels 
subsequent to the ovarian stimulation with GnRH agonist (long protocol) or with GnRH 
antagonist.  
Our analysis emphasizes the importance of the real usefulness of serum estrogen levels 
monitoring during ovarian stimulation.  
Previously, it was highly recommended to constantly monitor the patient response to drug 
stimulation, suggesting that the dynamic modifications of estrogen levels were reflecting the 
ovarian response to the stimulation. But, with our study, we found that there is no relation 
between dynamic changes and IVF outcome and that stopping the stimulation before the 
oocytes retrieval, in case of lowering level of final E2 levels, should not be recommended. 
Moreover, since there are no significant differences between IVF outcomes in patient with 
different trends of increasing E2 levels, the routine of serial E2 levels  monitor extended to all 
patients, regardless their characteristics, doesn’t add any benefits and can increase the cost of 
the procedure.  
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In order to reduce health financial costs we could rather monitor the follicular growth with 
serial scans and serial E2 levels assessment limited to patients at high risk of OHSS, to strictly 
follow the response of these patients and to closely vary the therapy; on the contrary, serial 
scans could be the only method of monitoring in patients with normal or poor ovarian 
response.  
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CHAPTER 3 – TARGET 2 
 
Improving the safety of COH treatments aimed at IVF,  in order to prevent IVF 
complications 
 
3.1 Triggering with different doses of gonadotropin releasing hormone (gnrh) agonist in 
oocyte donor cycles: a randomized clinical trial (RCT). 
 
 
3.1.1 GNRH AGONIST TRIGGERING: A REVIEW OF LITERATURE  
 
The administration of HCG to induce final oocyte maturation has been used for decades and 
has been considered the gold standard during ovarian stimulation for IVF cycles. Recently, 
however, it has been suggested that the time has come for a paradigm shift in triggering 
policies (Humaidan and Alsbjerg, 2014; Humaidan and Polyzos, 2014). Although HCG 
effectively induces oocyte maturation and maintains excellent pregnancy rates during the IVF 
process, the prolonged half-life of HCG compared with natural LH promotes supra- 
physiological luteal steroid levels and the development of multiple corpora lutea, resulting in 
a potential increased risk of ovarian hyperstimulation syndrome (OHSS). Therefore, the use 
of alternate modalities to induce oocyte maturation to prevent OHSS, such as gonadotropin 
releasing hormone agonist (GnRHa) has been the focus of research for years.  
In 1988, Itskovitz et al. for the first time published a case report in which they describe the 
use of GnRH-agonist in two patients that in the previous cycle had developed ovarian 
hyperstimulation syndrome (OHSS) after hCG treatment; none of the them in developed signs 
of OHSS in this cycle. 
The GnRHa trigger concept gained some interest in the late 1980s and early 1990s. However, 
with the introduction of GnRHa for pituitary down-regulation prior to IVF/ICSI treatment 
(Porter et al., 1984), this concept was clearly not applicable, as the simultaneous use of GnRHa 
for down-regulation and triggering of final oocyte maturation is not possible.  
With the introduction of the GnRH antagonist (Albano et al., 1997; Borm and Mannaerts, 
2000; Itskovitz-Eldor et al., 1998), it became again possible to trigger ovulation with a bolus 
of GnRHa as an alternative to HCG, as GnRHa will displace the GnRH antagonist from the 
GnRH receptor in the pituitary and elicit a surge of gonadotropins (LH and FSH). However, 
there are significant differences between the GnRHa-induced surge of gonadotropins and that 
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of the natural cycle. Thus, the LH surge of the natural cycle is characterized by three phases, 
with a total duration of 48 h (Hoff et al., 1983), as compared with the GnRHa-induced LH 
surge, which consists of two phases for a total of 24–36 h (Itskovitz et al., 1991).  
 
 
 
This leads to a significantly reduced total amount of gonadotropins released from the pituitary 
when GnRHa is used to trigger final oocyte maturation (Gonen et al., 1990; Itskovitz et al., 
1991). This per se could induce a defective luteal phase (Balasch et al., 1995; Segal and 
Casper, 1992), which needs a modification of the standard support in order to prevent a 
negative IVF outcome (Humaidan et al., 2010).  
However, a possible advantage of GnRHa for triggering of final oocyte maturation in 
comparison with hCG is the simultaneous induction of a FSH surge comparable to the surge 
of the natural cycle. The role of the mid-cycle FSH surge in the natural cycle is not fully 
understood, but FSH has been shown to induce LH receptor formation in the luteinizing 
granulosa cells thus optimizing the function of the corpus luteum. Moreover, FSH specifically 
seems to promote oocyte nuclear maturation, i.e. resumption of meiosis (Zelinski-Wooten et 
al., 1995; Yding Andersen et al., 1999) and cumulus expansion (Stickland and Beers, 1976; 
Eppig, 1979).  
Interestingly, several studies reported the retrieval of more mature oocytes after GnRHa 
trigger, which could be an effect of a more physiological surge including a FSH surge as well 
as an LH surge (Imoedemhe et al., 1991a; Humaidan et al., 2005, 2009a, 2010; Oktay et al., 
2010).  
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Several studies, reported a reduction of OHSS incidence in the egg donation program:  it has 
been demonstrated through retrospective studies (BS Shapiro et al., 2007; Hernandez ER et 
al., 2009) and randomized clinical studies (Acevedo B. et al. , 2006; Galindo et al., 2009). 
However, until now the greatest advantage of GnRHa triggering in ovarian hyperstimulation, 
is the total elimination of OHSS. This has led to the fact that GnRHa triggering is now the 
method of choice in many oocyte donation programs, resulting in a high good quality oocyte 
yield, an elimination of OHSS, a higher degree of patient convenience and an excellent 
pregnancy rate in recipients (Hernandez et al., 2009; Bodri et al., 2009).  
Currently, we don’t know what is the optimal dose of GnRH agonist.  
In 1996, Parneix et al, compared in the same patients undergoing IVF, different doses of 
different molecules of GnRH-agonist, with different routes of administration (subcutaneous 
injection and nasal spray). Subsequent studies used single doses of a same GnRH-analogue, 
such as Triptorelin 0.2 mg, Buserelin 0.5 mg, Leuprolide acetate 1 mg and 1.5 mg (Bodri et 
al., 2009; Hernandez et al., 2009; Papanikolaou et al., 2011, Humaidan et al., 2010; Castillo 
et al., 2010). 
 
The main purpose of our randomized clinical trial was to compare different doses of the same 
GnRH-agonist molecule, the Triptorelin, with the aim to identify any diversity in ovarian 
performance and in the number of good embryos. 
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3.1.2 MATERIALS AND METHODS  
 
We enrolled in the egg donation program, 60 oocyte donors who undergone controlled ovarian 
hyperstimulation with GnRH antagonist at the IVI clinic of Barcelona. The recruitment period 
is between February and May 2015.   
We identified three arms of randomization, with identification of three different treatment 
groups, each consisting of 20 clinical cases: 
a) Triptorelin 0.1 mg   
b) Triptorelin 0.2 mg   
c) Triptorelin 0.3 mg   
 
The enrollment was carried out by following the protocols of IVI clinic, in accordance with 
the provisions of the Royal Decree, legislative document regulating egg donation in Spain. 
Each patient underwent a preliminary clinical investigation, with a focus on family history, in 
order to identify hereditary diseases (chromosomal disorders, genetic disorders, psychiatric 
disorders, etc ...) representatives factor of exclusion from the oocyte donation program. 
Similarly, we investigated physiological, medical history, obstetrical and gynecological 
history of each patient, and were specified any previous eggs donation cycles.  
During the first visit, the patients were informed of the objectives and requirements of the 
study and was delivered their informed consent, got signed before any invasive tests. Similarly 
it was then assigned an identification number. 
In a later meeting the patients had a gynecological examination, with associated pelvic 
transvaginal ultrasound evaluation, performed in the early follicular phase, in order to exclude 
gynecological diseases (malformations, ovarian diseases, etc ...) and to carry out the antral 
follicle count (AFC), fundamental parameter as strongly predictive of ovarian reserve, so the 
response to controlled ovarian stimulation treatments. 
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Inclusion Criteria  Exclusion criteria 
Age 18-35 years Polycystic ovary syndrome 
18<BMI<28 Comorbidity 
AFC >10  
Negative medical History  
 
 
Each patient underwent controlled ovarian stimulation with GnRH antagonist protocol, 
performed by daily administration of r-FSH (follitropin alfa-and-follitropin beta) from the 2nd 
or 3rd day of the menstrual cycle, with doses ranging from 150- 225 IU / day sc. GnRH 
antagonist was administered according the flexible scheme (ganirelix or cetrorelix 0.25 
mg/die ). 
The final trigger was made when at least 3 follicles> 18 were available, by the administration 
of Triptorelin, with different doses, depending on the randomization arm. The oocyte 
collection was carried out 36 h after induction. 
The main outcomes were the proportion of retrieved and mature oocytes.  
The secondary outcomes were the proportion of fertilized oocytes (FR), proportion of good 
embryos (transferred + vitrified) in relation to obtained embryos, and the incidence of ovarian 
hyperstimulation syndrome (OHSS). 
For the statistical analysis SPSS 17, Chi-square and Kruskal-Wallis tests were used, p<0.05 
considered significant.  
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3.1.3 RESULTS 
 
Of a total of 60 patients enrolled, data for 51 patients were analyzed, randomized into three 
arms:  
- 18 patients (35.3%) performed the final trigger with Triptorelin 0.1 mg;  
- 17 patients (33.3%) with Triptorelin 0.2 mg  
- 16 patients (31.4%) with 0.3 mg Triptorelin.  
 
9 donors were excluded from the analysis, 2 because we did not complete the donation and 
7 because we performed conventional IVF rather than ICSI. 
 
The number of patients per arm is considered equivalent (χ2 = 0.12; p = 0.943; chi-squared 
test). 
 
 
Randomization Class   N cases  Percentage 
Triptorelin 0,1 mg   18  35,3 
Triptorelin 0,2 mg   17  33,3 
Triptorelin 0,3 mg   16  31,4 
Totale  51  100 
 
The average age of treated patients was 25.2 years (median 25 years) with a minimum of 18 
and a maximum of 35 years. The data were also stratified for the randomization classes. No 
statistically difference was not observed in the three study groups (p = 0.865). 
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  N media SD mediana Min Max 
 
Age 
(yrs) 
0,1 mg 18 25,6 5,0 27,0 18 35 
0,2 mg 17 24,7 2,8 25,0 21 33 
0,3 mg 16 25,4 4,9 24,5 19 34 
 Total  51 25,2 4,3 25,0 18 35 
 
 
The mean BMI of the analyzed population is equal to 22.2 kg / m2, with a minimum of 18.3 
and a maximum of 26.5 kg / m2. 
 
 
  N media SD mediana Min Max 
 
BMI 
(kg/m2) 
0,1 mg 18 22,2 2,2 22,2 18,7 26,5 
0,2 mg 17 22,1 2,4 21,9 18,3 26 
0,3 mg 16 22,4 2,1 22,2 19 26,2 
 Total  51 22,2 2,2 22,2 18,3 26,5 
 
P=0,920 
 
The mean duration of ovarian stimulation was 8.9 days (median 9 days), in line with what is 
commonly found in clinical practice. The average time, in days, of the administration of a 
GnRH-antagonist was equal to 3.9 days, a 4-day median, a minimum of 2 and a maximum of 
5 days, with no difference between classes of randomization. 
About the type of u-FSH administered, no significant differences were observed in the study 
population, without modification of results after sample stratified by randomization classes 
(p=0,837) 
The mean total number of ovarian follicles found in ultrasound (US) evaluation on the 
triggering day was 23.4 (median 23 follicles), while the mean number of oocytes retrieved 
was a 18,8 follicles, with a mean of 14.7 MII oocytes.  
 
  
49 
 
 
 
The yield of ovarian response was calculated as the number of mature oocytes (MII) recovered 
in relation to the number of ovarian follicles with a diameter ≥14 mm measured at US 
evaluation. The average yield in patients amounted to 96.6% (median 92.3%), with no 
statistical significance.  
The average number of fertilized oocyte was 10.6 and were obtained an average number of 
good embryos of 6.4 (median: 7 embryos). The mean number of embryos transferred was 1.7 
embryos (median: 2 embryos) 
 
Note: In 14 donors part of the oocytes recovered were inseminated and part vitrified, thus we 
lack some data on the number of fertilized eggs and the number of embryos obtained. 
 
 
Primary Outcomes 
Primary objective of the study was to assess whether different doses of the same agonist affect 
ovarian performance. In particular, the our primary outcomes were: 
a) number of oocytes retrieved in relation to the number of ovarian follicles ≥14 mm 
in diameter, reported on the trigger day. (COCs / foll≥14) 
b) number of mature oocytes (MII) in relation to the number of oocytes retrieved at 
pick-up 
Both the proportion of retrieved oocytes (COCs) in relation to follicle >14mm on the 
triggering day (122.3% group 1, 131.5% group 2, 114.3% group 3) and the proportion of 
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mature oocytes in relation to COCs (81% group 1, 76.6% group 2, 86.8% group 3) were 
comparable in the groups. 
 
 
 
 
 
 
 
            Secondary outcomes  
 
a) fertilization rate  
b) proportion of good embryos (transferred + vitrified) in relation to obtained embryos  
c) OHSS rate   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For the secondary outcome, we analysed data from 37 donors and in 14 the oocytes were 
vitrified. 
 
a) Fertilization rate (oocytes fertilized / MII) 
We observed the fertilization rate of 79.9%, with a median of 83.3%, a minimum of 33.3% 
and a maximum of 100%, with no significant difference in relation to the dose administered 
Triptorelin. 
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b) Proportion of good embryos (transferred + vitrified) in relation to obtained embryos  
 
 
The proportion of good embryos (transferred + vitrified) in relation to obtained embryos was 
61,6% (57.7% group 1, 64.6% group 2, 61.4% group 3), with no differences in the three 
groups.  
 
 
 
c) OHSS rate 
There were no cases of moderate to severe OHSS. Only in 4 cases, the patients reported 
abdominal discomfort, in the absence of additional clinical data pathognomonic of OHSS. In 
particular, one case was observed in the group of patients treated with Triptorelin 0.1 mg and 
3 cases in the group treated with 0.2 mg Triptorelin for final oocyte maturation.  
The results confirm that the use of the agonists in the final trigger is a valid pharmacological 
strategy in the prevention of moderate/severe forms of OHSS. 
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3.1.4 DISCUSSION  
 
The use of GnRH-agonist (GnRH-a) for the trigger, as an alternative to hCG, today represents 
a valid therapeutic strategy in patients undergoing controlled ovarian stimulation. Their use 
has been made possible by the introduction, in the late '90s, of the GnRH antagonists (GnRH-
door) to prevent premature LH surge in IVF cycles.  
Several clinical studies published in the literature have demonstrated their efficacy in the 
induction of final oocyte maturation, because able to induce an LH peak. In particular, the 
GnRHa induced LH-surge consists of two phases: a short ascending limb (> 4 h) and a long 
descending limb (> 20 h), for a total of 24–36 h (Itskovitz et al., 1991). In contrast, the mid-
cycle surge of the natural cycle (Fig. 1) is characterized by three phases: a rapidly ascending 
phase lasting for 14 h, a plateau of 14 h and a descending phase of 20 h, in total 48 h (Hoff et 
al., 1983). 
It was also observed that the GnRH-a trigger, simultaneously defines a peak of FSH, similar 
to what occurs in the natural cycle, responsible for the formation of LH receptors in luteinized 
granulosa cells, the oocyte nuclear maturation and cumulus expansion (Stickland e Beers, 
1976; Eppig, 1979; Zelinski-Wooten et al., 1995;. Yding Andersen et al., 1999;. Yding 
Andersen, 2002), all aspects that probably correlate with the highest number of mature oocytes 
MII retrieved (Imoedemhe et al, 1991a; Humaidan et al, 2005, 2009a, 2010; Oktay et al, 
2010).  
Their use in clinical practice is mainly due to the need to reduce the incidence of ovarian 
hyperstimulation syndrome (OHSS), still one of the complications associated with ovarian 
stimulation in IVF cycles. 
In a meta-analysis published in 2011, a significantly lower incidence of OHSS in patients 
treated with agonist vs hCG was observed (OR 0.10 , 95% CI 0.01 to 0.82, I2 = 0%, P = 0.74; 
5 studies). Youssef at al., in 2011 had similar results in a RCT conducted in patients 
undergoing ovarian stimulation for egg donation (OR 0.06, 95% CI 0.01to0.31, I2 = 0%, P = 
0.96; 3 trials).  
Despite the potential advantages by the use of GnRh agonist to trigger final oocyte maturation, 
several studies reported a poor clinical outcome with an extremely high early pregnancy loss 
rate when GnRHa was used to trigger ovulation (Fauser et al., 2002; Humaidan et al., 2005; 
Kolibianakis et al., 2005). The poor results were attributed to a luteal phase insufficiency 
despite standard luteal phase support (LPS) with progesterone and estradiol. Thus, until now 
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the greatest advantage of GnRHa triggering in ovarian hyperstimulation, is the total 
elimination of OHSS. This has led to the fact that GnRHa triggering is now the method of 
choice in many oocyte donation programs, resulting in a high good quality oocyte yield, an 
elimination of OHSS, a higher degree of patient convenience and an excellent pregnancy rate 
in recipients (Hernandez et al., 2009; Bodri et al., 2009).  
Several studies proposed different molecules and different doses of GnRha to trigger final 
oocyte maturation.  
The aim of our study is to identify the optimal dose of the same GnRH agonist for the 
induction of final oocyte maturation. In our knowledge, this is the first randomized clinical 
trial that compare different doses of the same GnRh agonist to trigger final oocyte maturation.  
Our data show an average number of MII oocytes mature equal to 78% of the total of oocytes, 
with an ovarian efficiency (defined as the number of oocytes retrieved in relation to follicles 
≥ 14 mm in the triggering day) of 96.6%. 
The proportion of retrieved oocytes (COCs) in relation to follicle >14mm on the triggering 
day (122.3% group 1, 131.5% group 2, 114.3% group 3) and the proportion of mature oocytes 
in relation to COCs (81% group 1, 76.6% group 2, 86.8% group 3) were comparable in the 
groups. The results confirm that the use of GnRH agonists 36 hours before the oocyte retrieval 
contributes largely to the maturing oocyte. 
For the seconds endpoints, the FR (80.2% group 1, 76.5% group 2, 83.2% group 3) and the 
proportion of good embryos (transferred + vitrified) in relation to obtained embryos (57.7% 
group 1, 64.6% group 2, 61.4% group 3) didn’t differ significantly between the groups. 
Finally, no OHSS cases occurred in any of the groups. 
Performing an analysis of the individual arms of the randomization, we observed that the arm 
associated with the minimum dose of Tritorelin (0.1 mg) showed the same results of the 
groups treated with higher doses of the drug (0.2 mg and 0.3 mg). If this result was confirmed 
in subsequent surveys, it could represent primarily an advantage in terms of costs, with a 
reduction in health care costs.  
At the same time, it might be proposed an extension of the protocol in homologues IVF cycles: 
in this way it might be interesting to see whether, a reduction of GnRh agonist doses could 
have less negative impact on the luteal phase.  
Final trigger with 0,1 mg of Triptorelin could represent a standard dose, more safe not only in 
terms of OHSS rate reduction, but also for the luteal phase, improving the clinical and ongoing 
pregnancy rate, with a possible reduction of miscarriage rates.  
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3.2. Long term COH complications: metabolic, cardiovascular and oncological risk 
evaluation. An observational, retrospective study  
 
3.2.1 BACKGROUND 
 
Over the years, the scientific community has always paid attention to the possible side effects 
of these drugs, and in particular the possibility of developing cancer, particularly ovarian, 
breast and endometrium. It 'well known that hormonal factors may be involved in the etiology 
of certain cancers, in particular those of the female reproductive system.  
A significant number of scientific papers published in the literature has tried to address the 
possible long-term effects of ovulation-inducing drugs on cancer risk. Although early cohort 
findings raised concern regarding effects on ovarian cancer (1, 2), more recent findings have 
been largely reassuring (3, 4–6). Results regarding breast cancer are hard to interpret given 
that in the largest studies the risks have ranged from inverse relationships (7) to increased 
risks (4, 6) to no associations (9-14). The one site for which there is some consistency is that 
of endometrial cancer, with a number of studies suggesting possible risk increases (4, 10, 11, 
15, 16).  
Brinton LA. et al, in a retrospective cohort study, concluded that there were no significant 
relationships of IVF exposures to the risks of breast, endometrial, or ovarian cancers. 
However, compared with women with no fertility treatment, the HR for ovarian cancer 
associated with IVF was 1.58 (95% confidence interval [CI] 0.75–3.29), with higher risk 
among those receiving four or more cycles (HR 1.78, 95% CI 0.76–4.13). There was also a 
nonsignificantly elevated risk for endometrial cancer among women who received 1–3 IVF 
cycles (HR 1.94, 95% CI 0.73–5.12), but additional cycles were associated with less risk. In 
contrast, the risk of in situ cervical cancer was significantly reduced and invasive cervical 
cancer nonsignificantly reduced among women receiving IVF as well as other fertility 
treatments.  
van den Belt-Dusebout, in a recent study published in 2016, concluded that Breast cancer risk 
in IVF-treated women was not significantly different from that in the general population (SIR, 
1.01 [95% CI, 0.93-1.09]) and from the risk in the non-IVF group (HR, 1.01 [95% CI, 0.86-
1.19]). The cumulative incidences of breast cancer at age 55 were 3.0% for the IVF group and 
2.9% for the non-IVF group (P = .85). The SIR did not increase with longer time since 
treatment (≥20 years) in the IVF group (0.92 [95% CI, 0.73-1.15]) or in the non-IVF group 
(1.03 [95% CI, 0.82-1.29]). Risk was significantly lower for those who underwent 7 or more 
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IVF cycles (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF cycles and after poor response to the 
first IVF cycle (HR, 0.77 [95% CI, 0.61-0.96] for <4 vs ≥4 collected oocytes). 
About the cardiovascular and metabolic risk in patients undergoing IVF, to date there are few 
data in literature. It consists mostly of data collected only in cases of ovulatory infertility. In 
particular, in patients undergoing homologous IVF cycles, it was observed that PCOS patients 
have seven times increased risk of developing myocardial infarction (18). Moreover, the 
condition of oligomenorrhea, typical of the syndrome, it is seen to be associated with an 
increased risk of cardiovascular disease (CVD) (19).  
Recent studies report a temporary increase of blood pressure associated to the use of oral 
contraceptives, as well as to a potentially higher risk of developing cardiovascular disease. 
(20-21). Potential mechanisms involved in the elevation of blood pressure probably involve 
the renin-angiotensin system: in particular, in patients taking CO was observed an elevation 
of angiotensinogen levels along with an abnormal activation of the renin systems.  
About the cardiovascular and metabolic risk of patients undergoing IVF, recent studies report 
an increased risk of preeclampsia, which is also associated with an increased risk of preterm 
birth, gestational diabetes, postpartum hemorrhage and low birth weight, with risk levels 
ranging from + 20% to + 60% compared to pregnancies arisen spontaneously (22). In relation 
to the mode of delivery, caesarian-section increases of + 50% compared to spontaneous 
vaginal delivery. 
It is well established that advanced maternal age is one of the risk factors that most correlates 
with adverse maternal and fetal outcomes. A recent meta-analysis showed that the risk of 
developing preeclampsia and gestational hypertension is greatly increased in pregnancies 
obtained from egg donation compared to those obtained by homologous IVF techniques (OR 
2:54; 95% CI; p <0.001) or by spontaneous conception (OR 4:34 ; 95% CI; p <0.001) (23). 
Similar data were also confirmed by other studies in the literature (24,25). In 
pregnancy obtained from egg donation it would seem to triggeran immune response 
against maternal fetal allogeneic antigens, responsible for abnormal placentation. This 
leads to the release into the maternal circulation of anti-angiogenic and pro-inflammatory 
mediators that are wing behind the development of endothelial dysfunction leading to 
increased peripheral vascular resistance.  
No more data we found about long term risks in IVF patients.   
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3.2.2 AIMS OF THE STUDY 
Retrospective observational study to assess a possible interlinkages between To assess long-
term risk of cardiovascular, metabolic and oncological complications after ovarian stimulation 
for IVF. We tried to investigate too a possible correlation between the onset of pregnancy 
complication and cardiovascular and metabolic disease after a long time from IVF treatments 
 
3.2.3 MATERIAL AND METHODS 
We enrolled all patients who undergone 2 ore more homologues IVF treatments from 2000 to 
2010 at the IVI clinic of Barcelona.  
We created an "ad hoc questionnaire" containing epidemiological data (BMI, age, etc.) and 
current medical history. The information relating to the treatment phase were recovered from 
elettronic database of IVI clinic (Sivis).  
In particular, we collected data related to: 
- infertility duration 
- type of infertility 
- causal factor 
- type of protocol used 
- days of stimulation 
- total dose of gonadotropins 
- number of oocytes retrieval 
- number of transferred embryos 
- eventual diagnosis pre facility 
- fertilization rate 
- implantantion rate 
- clinical pregnancy rate 
- Cycle number successfully 
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3.2.4 PRIMARY ENDOPOINTS 
- Hypertension disease 
- Diabetes 
- Dyslipidemia  
 
SECONDARY ENDPOINTS:  
- Breast cancer 
- Gynaecological  cancer (endometrial cancer, ovarian cancer) 
 
Results 
In order to carry out a scientific work with a good robustness from the statistical point of view, 
we decided to collect all the data related to homologous  IVF cycles carried out from 2000 to 
2016. Therefore, we are waiting the last born conceived in 2016 for the completion of the data 
analysis.  
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